Efficacy of Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Edema. Issue 5 (September 2015)

• Record Type: Journal Article
• Authors: Bonnin, Sophie; Dupas, Bénédicte; Sanharawi, Mohamed El; Perol, Julien; Erginay, Ali; Tadayoni, Ramin; Massin, Pascale
• Is Part Of: European journal of ophthalmology. Volume 25:Issue 5(2015)
• Page Start: 448
• Page End: 453
• Publication Date: 2015-09
• Subjects: Dexamethasone -- Diabetes -- Intravitreal implant -- Macular edema -- Vitrectomy; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.5301/ejo.5000581
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To assess the efficacy of a single dexamethasone intravitreal implant (Dex-I) injection for the treatment of diabetic macular edema (DME). Methods: This was a retrospective chart review of 39 eyes (34 consecutive patients). Best-corrected visual acuity (BCVA), central macular thickness (CMT), and increase in intraocular pressure (IOP) (>24 mm Hg) were analyzed before treatment and 2 and 4 months after injection. Results: Preoperative mean CMT was 559 ± 111 μm and decreased to 338 ± 84 and 477 ± 140 μm 2 and 4 months after injection, respectively. Although all eyes showed a significant decrease in CMT 2 months after injection (p<0.0001), a recurrence of the macular edema was observed 4 months after injection in 79% of eyes. Mean BCVA improvement (logMAR) was 0.13 ± 0.18 (p<0.0001) and 0.07 ± 0.21 (p = 0.049) 2 and 4 months after injection, respectively, without significant difference between vitrectomized and nonvitrectomized eyes. Eight eyes (21%) developed reversible increase in IOP 2 months after injection. Conclusions: Thirty percent of DME eyes had gained more than 2 logMAR lines 2 months after Dex-I injection and safety was good. Visual acuity gain was maintained 4 months after injection despite a recurrence of edema in most cases.